FDA's Billy Dunn Resigns from Post Amidst Drug Scandal on Alzheimer's—What Happened? The recent controversy on the Alzheimer's drug approvals already had an executive stepping down. by Isaiah Richard
Chatbots Could Be Suffering from Confirmation Bias When Tackling Controversial Issues: John Hopkins Study